5969-19-7

Basic information

• Product Name: Ethyl 3-(7-hydroxy-4-methyl-2-oxo-2H-chromen-3-yl)propanoate
• Synonyms: Ethyl 3-(7-hydroxy-4-methyl-2-oxo-2H-chromen-3-yl)propanoate;3-(7-Hydroxy-4-methyl-2-oxo-2H-chromen-3-yl)-propionic acid ethyl ester
• CAS NO: 5969-19-7
• Molecular Formula: C₁₅H₁₆O₅
• Molecular Weight: 276.28454
• Mol File: 5969-19-7.mol
• Article Data: 9

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.368g/cm³
• Refractive Index: 1.642
• CAS DataBase Reference: Ethyl 3-(7-hydroxy-4-methyl-2-oxo-2H-chromen-3-yl)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 3-(7-hydroxy-4-methyl-2-oxo-2H-chromen-3-yl)propanoate(5969-19-7)
• EPA Substance Registry System: Ethyl 3-(7-hydroxy-4-methyl-2-oxo-2H-chromen-3-yl)propanoate(5969-19-7)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 5969-19-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C16H15ClN2O2S/c1-16(2)7-11-13(12(20)8-16)22-15(18-11)19-14(21)9-5-3-4-6-10(9)17/h3-6H,7-8H2,1-2H3,(H,18,19,21)

Upstream product

• 5852-06-2 3-(7-hydroxy-4-methyl-2-oxo-2H-chromen-3-yl)propionic acid 
• 150-19-6 O-methylresorcine 
• 1501-06-0 diethyl 2-acetylglutarate 
• 108-46-3 recorcinol 
• 57054-17-8 ethyl 2-acetyl-5,5-dichloropent-4-enoic acid 
• 936739-45-6 3-(3,3-dichloroprop-2-enyl)-7-hydroxy-4-methyl-2H-chromen-2-one 
• 936739-52-5 3-(7-hydroxy-4-methyl-2-oxo-2H-chromen-3-yl)propanoyl chloride 
• 64-17-5 ethanol 

Downstream Products

• 777857-41-7 3-(3',5'-dimethyl-7'-oxofuro[3,2-g]chromen-6'-yl)propanoic acid 
• 777857-43-9 (3'-tert-butyl-5'-methyl-7'-oxo-7H-furo[3,2-g][1]benzopyran-6'-yl)propionic acid 
• 777857-46-2 3-(2',5'-dimethyl-7'-oxo-3'-phenylfuro[3,2-g]chromen-6'-yl)propanoic acid 
• 777857-60-0 3-{4'-methyl-2'-oxo-6',7',8',9'-tetrahydrobenzo[4,5]furo[3,2-g]chromen-3'-yl}propanoic acid 

Relevant articles and documents

Modified coumarins. 9. Synthesis of amino-acid derivatives of 3-(2,3,5-trimethyl-7-oxofuro-[3,2-g]chromen-6-YL)propanoic acid

Furocoumarins modified by amino acids were prepared by condensation of the N-hydroxysuccinimide ester of 3-(2,3,5-trimethyl-7-oxofuro[3,2-g]chromen-6-yl) propanoic acid with amino acids.

A focused structure-activity relationship study of psoralen-based immunoproteasome inhibitors

The immunoproteasome is a multicatalytic protease that is predominantly expressed in cells of hematopoietic origin. Its elevated expression has been associated with autoimmune diseases, various types of cancer, and inflammatory diseases. The development of immunoproteasome-selective inhibitors with non-peptidic scaffolds remains a challenging task. Here, we describe a focused series of psoralen-based inhibitors of the β5i subunit of the immunoproteasome with different substituents placed at position 4′. The most promising compound was further evaluated through changes at position 3 of the psoralen ring. Despite a small decrease in the inhibitory potency in comparison with the parent compound, we were able to improve the selectivity against other subunits of both the immunoproteasome and the constitutive proteasome. The most potent compounds discriminated between both proteasome types in cell lysates and also showed a decrease in cytokine secretion in peripheral blood mononuclear cells.

PSORALEN DERIVATIVES AS NON-PEPTIDIC INHIBITORS OF CHYMOTRYPSIN-LIKE ACTIVITY OF THE IMMUNOPROTEASOME

This invention relates to new inhibitors of chymothrypsin-like activity of the immunoproteasome (inhibitors of β5? or LMP7 subunit) with the general formula (I), where substituents are described in patent description. Compounds can be in the form of pure enantiomers or as racemic mixtures, or in the form of pharmaceutically acceptable salts. The present invention relates to the use of these inhibitors for the treatment of diseases where immunoproteasome activity is increased.